Lumanity announced the acquisition of Endpoint Outcomes, a company specializing in harnessing the voice of patients to document the impact of treatments on health-related quality of life. The highly complementary acquisition of Endpoint Outcomes strengthens Lumanity’s value demonstration capabilities by creating a comprehensive, global health economics and outcomes research (“HEOR”) suite of services.
Chris Evans, CEO of Endpoint Outcomes, said, “We are excited to join Lumanity and proud to be part of a company with a purpose that aligns with our own. We've built a great organization and believe that joining Lumanity is the next step in this journey, allowing us to continue to keep patients at the heart of everything we do. With new colleagues and capabilities to tap into, we now have the ingredients to build ground-breaking solutions and drive even greater value for our clients and their patients.”
Endpoint Outcomes is a leader in the development and implementation of patient-centric clinical outcomes assessments (“COAs”). Endpoint’s team of experts works with its clients to help define the value of new medical innovations and generate evidentiary support of the highest caliber for regulators, clinicians, payers, and patients. The addition of Endpoint’s proven COA capability is critical to Lumanity’s mission of demonstrating the value of medical advances to optimize patient access, which requires the consideration and integration of economic, patient, and clinical outcomes. The convergence of health economics and patient-centered outcomes research is necessary to support payer evaluations and health technology assessments for Lumanity’s most important clients.
Jon Williams, CEO of Lumanity, said, “We are thrilled to welcome Endpoint as part of Lumanity. We were immediately impressed with the strength of the team, the quality of Chris’s leadership, and how well our views aligned on the strategic opportunities available to us as a combined force. We look forward to working with our new colleagues to define and build market-leading, patient-centered research services to address both HTA and payer needs, and we are confident that our work will yield innovative new solutions for our clients and partners.”
Lumanity was formed by bringing together the expertise and capabilities of several exceptional organizations, including Cello Health, BresMed, Guidemark Health, Cyan Health, Zipher Medical Affairs, and Innovative Edge. The addition of Endpoint Outcomes further enhances Lumanity’s unique and diverse collection of deeply experienced industry pioneers, data luminaries, subject matter experts, and proven problem solvers with advanced clinical, scientific, and functional capabilities.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox!
Sign up now!